Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 3
Semaglutide plus SGLT2 inhibitors in China
A Chinese real-world analysis described six-month metabolic outcomes in adults using semaglutide with an SGLT2 inhibitor.
Semaglutide and taste in mice
A 2026 mouse study found preserved taste responses during chronic semaglutide treatment, despite changes in sucrose-directed behavior.
A two-timepoint semaglutide brain map
A mouse study mapped semaglutide-linked activity across more than 500 brain areas using two timepoints, finding 24 engaged regions.
Surgery vs semaglutide and tirzepatide
A 44,025-person record study associated bariatric surgery with more weight loss than semaglutide or tirzepatide, but it was not randomized.
Tirzepatide response after eight weeks
A SURMOUNT post hoc analysis linked early tirzepatide weight response with larger 72-week changes, while later responders still lost weight.
Tirzepatide and lithium safety signal
A 23-person cohort found a lithium safety signal after tirzepatide initiation in bipolar disorder. It cannot estimate the risk or prove causation.
Adolescent GLP-1 use: what remains unknown
A 2026 commentary reviews skeletal, reproductive and psychosocial questions around semaglutide and other GLP-1 drugs in adolescents.
GLP-1 Records in Diabetic Neuropathy
A cross-sectional hospital study found more documented illness among neuropathy patients with GLP-1-based medication records, but no causal effect.
GLP-1 Heart Failure Meta-analysis
A 14-trial meta-analysis found a favorable signal in HFpEF, while evidence for GLP-1 receptor agonists in HFrEF remained limited.
GLP-1 rodent tumor evidence reassessed
A 2026 review argues that GLP-1 rodent thyroid tumors reflect a human-irrelevant mechanism, but long-term human risk is not settled.
Hypothalamic Obesity in Craniopharyngioma
A 2026 review found different obesity patterns after pediatric and adult craniopharyngioma, while direct age comparisons remain absent.
MASH drug cost-effectiveness model
A U.S. model found semaglutide and tirzepatide cost-effective versus standard care for MASH, with major uncertainty around prices and assumptions.